The global gunshot injuries treatment market size is projected to grow from USD 16.3 Mn in 2026 to USD 28.2 Mn by 2033, registering a compound annual growth rate (CAGR) of 8.2% during the forecast period (2026-2033). This growth is mostly due to the increasing incidence of firearm-related injuries, rising demand for advanced trauma care and emergency medical services, growing healthcare infrastructure investments, and continuous advancements in surgical treatment and wound management technologies.
The rising incidence of firearm-related injuries and trauma cases worldwide is increasing demand for advanced gunshot injury treatment solutions. There is a growing trend of hospitals, military medical facilities, and emergency medical services opting for bleeding control technologies, trauma bandages, and surgical hemostasis products to enhance chances of survival in emergencies.
Moreover, the World Health Organization indicates that about 4.4 million people die from injuries each year all over the world. This highlights the need for trauma care systems and bleeding control products used during surgeries.
Technological developments in the fields of hemorrhage management and trauma care have greatly improved the effectiveness of treatments for victims of gunshots. Advanced technologies like expandable sponge bandages, coagulating matrices, and fast coagulant gels help doctors better manage patient situations both in emergencies and surgeries. The increasing use of these technologies in military combat medicine, ambulance operations, and civilian trauma clinics can be attributed to their efficiency in reducing blood loss and saving lives.
According to the U.S. Food and Drug Administration, several advanced hemostatic and wound treatment technologies have received regulatory approvals in recent years to support emergency trauma care and surgical bleeding management applications.
|
Current Event |
Description and its Impact |
|
Rising Firearm Violence and Trauma Cases Across the U.S. |
|
|
Increasing Military Modernization and Emergency Preparedness Programs |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
XStat is expected to capture the largest market share by 2026 in the gunshot wounds treatment market, contributing about 46% of the total market size. This is due to the rise in the use of hemostasis techniques in military combat medicine, trauma, and bleeding management applications globally.
In January 2026, the Naval Medical Research Command announced that the XSTAT P15 wound treatment device received FDA 510(k) clearance in partnership with RevMedx. The advanced hemorrhage control device was specifically developed for treating narrow-entry gunshot and shrapnel wounds in combat and emergency environments.

To learn more about this report, Request Free Sample
North America is estimated to contribute around 43% towards the global market share of gunshot injuries treatment by 2026 owing to the prevalence of firearm injuries, well-established trauma facilities, and adoption of hemorrhage control devices in this region. North America is marked by robust health care expenditures, mature emergency response mechanisms, and growing adoption of advanced wound care products.
Technological innovations are contributing towards regional market growth. Firms in trauma care and hemorrhage management are introducing highly sophisticated battlefield and emergency response products for improving survival rates. The growing number of military modernization programs and increasing spending on emergency management systems are also driving market growth in the United States and Canada.
In January 2026, the Naval Medical Research Command announced FDA 510(k) clearance for the XSTAT P15 device developed with RevMedx.
Asia Pacific is expected to emerge as the region with the fastest growth rate between 2026 and 2033 owing to the development of healthcare infrastructures, emergency trauma treatment facilities, and technological advancements in wound management technology, especially in countries like China, India, and Japan.
The region is witnessing rapid expansion of trauma centers and emergency medical response systems. Urbanization, vehicular accidents, and emergencies requiring surgery and bleeding control products have led to increased product demand.
According to the World Health Organization, injuries account for nearly 4.4 million deaths globally every year, increasing the importance of emergency trauma treatment systems across developing economies in Asia Pacific.
The gunshot injuries treatment market in the U.S. is projected to grow at a stable pace in the forecast period. The growth is primarily attributed to the rise in the number of gun injuries, increased investments in trauma centers, rising adoption of innovative hemorrhage control solutions, and robust government expenditure on military healthcare services.
According to the CDC, there are more cases of non-fatal gunshot wounds than fatalities, and over 70% of medically attended gunshot wounds are due to assaults. The figures are expected to fuel the demand for innovative hemorrhage control technology,
China is anticipated to become an emerging market for gunshot injuries treatment technology solutions over the forecast period. Factors driving market growth include increased healthcare infrastructure development, improved emergency trauma response networks, increased utilization of surgical wound care products, and enhanced government preparedness programs.
Modernization of trauma centers and emergency medical care services is becoming a significant growth factor in China. Increased investments in hospitals' infrastructure and equipment have increased the availability of trauma treatment devices such as surgical agents for controlling hemorrhages and bleeding.
In February 2025, MicroPort Official Website announced that its Firelimus Drug-Coated Balloon Catheter received NMPA market approval in China.
Some of the major key players in Gunshot Injuries Treatment are RevMedx, Inc., Baxter International Inc., Medtrade Products Ltd., Stryker Corporation, Johnson & Johnson MedTech, 3M Health Care, Teleflex Incorporated, Smith & Nephew, B. Braun SE, and Zhejiang Haichuang Medical Device Co., Ltd.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 16.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.2% | 2033 Value Projection: | USD 28.2 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
RevMedx, Inc., Baxter International Inc., Medtrade Products Ltd., Stryker Corporation, Johnson & Johnson MedTech, 3M Health Care, Teleflex Incorporated, Smith & Nephew, B. Braun SE, and Zhejiang Haichuang Medical Device Co., Ltd. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients